Dermal Fillers vs Cosmetics vs Medicines: Hong Kong Borderline Classification After GN-00

The Classification Question That Defines Your Hong Kong Market Access

An injectable hyaluronic acid syringe arrives at Hong Kong customs. The product is CE marked in the EU as a Class IIb medical device. It is approved by the NMPA in Mainland China as a Class III medical device. The manufacturer markets it for "facial wrinkle correction and lip augmentation."

Under which Hong Kong regulatory framework does this product belong?

• Medical device — regulated under the Medical Device Administrative Control System (MDACS)
• Pharmaceutical product — regulated under the Pharmacy and Poisons Ordinance (Cap. 138)
• Cosmetic product — regulated under the Consumer Goods Safety Ordinance (Cap. 456)
• None of the above — the product falls into a regulatory gap

Before May 2026, the answer was genuinely uncertain. After May 2026, the answer is clearer — but the classification logic still requires careful analysis. This guide explains how Hong Kong draws the borderline between medical devices, pharmaceuticals, and cosmetics for dermal fillers, how this compares to the EU and US approaches, and what it means for your product.

Three Regulatory Frameworks, One Product

Framework 1: MDACS (Medical Devices)

Governing body: Medical Device Division (MDD), Department of Health

Legal basis: GN-00:2026-1(E), effective 13 May 2026

Scope: Injectable dermal fillers and mucous membrane fillers are now listed in Appendix 1 of GN-00 as items treated as medical devices under MDACS.

Key definition (Clause 2.38): A medical device is any instrument, apparatus, material, or other article intended to be used for purposes such as diagnosis, prevention, monitoring, treatment, or alleviation of disease; or compensation for injury or handicap; or investigation, replacement, or modification of the anatomy — and which does not achieve its primary intended action by pharmacological, immunological, or metabolic means.

Practical implication: Dermal fillers that work primarily by physical means (volume replacement, structural support) can be listed as medical devices under MDACS, even if the stated purpose is purely cosmetic.

Framework 2: Pharmacy and Poisons Ordinance (Pharmaceutical Products)

Governing body: Pharmacy and Poisons Board, Department of Health

Legal basis: Pharmacy and Poisons Ordinance (Cap. 138)

Scope: Products intended for human parenteral injection are, in general, regarded as pharmaceutical products under Cap. 138, per the updated Guidance Notes on Classification endorsed on 23 April 2026.

Key principle: Parenteral products are inherently high risk because they enter systemic circulation or human tissue directly, bypassing the body's natural defense mechanisms. They pose immediate and potentially life-threatening risks if sterility, quality, or handling is compromised.

Practical implication: Injectable products are presumed to be pharmaceutical products by default. The GN-00 Appendix 1 listing creates a specific exception for dermal fillers that meet the medical device definition — but the pharmaceutical framework remains the default for injectable products that do not qualify.

Framework 3: Consumer Goods Safety Ordinance (Cosmetics)

Governing body: Customs and Excise Department (enforcement); no pre-market approval

Legal basis: Consumer Goods Safety Ordinance (Cap. 456) and Consumer Goods Safety Regulation (Cap. 456A)

Scope: Topical cosmetic products (creams, lotions, serums) that are not pharmaceutical products and not medical devices.

Key limitation: Injectable products are not cosmetics. This is clear under Hong Kong law and consistent with international practice. Any product administered by injection is outside the scope of cosmetics regulation, regardless of the stated purpose.

Practical implication: Dermal fillers cannot be regulated as cosmetics in Hong Kong. This is not a borderline question — it is definitively outside the cosmetics framework.

The Classification Decision Tree for Dermal Fillers in Hong Kong

Step 1: Is the Product Injectable?

If the product is administered by injection (intradermal, subcutaneous, submucous), it is not a cosmetic product. Proceed to Step 2.

If the product is topical (cream, serum, mask), it may be a cosmetic product under Cap. 456. Topical products are outside the scope of this analysis.

Step 2: Does the Product Have a Pharmacological Mode of Action?

If the product's primary intended action is achieved by pharmacological, immunological, or metabolic means, it is a pharmaceutical product under Cap. 138. Examples: botulinum toxin (Botox), injectable vitamins, platelet-rich plasma with active biological components.

If the product's primary intended action is achieved by physical or mechanical means (volume replacement, structural support, tissue augmentation), proceed to Step 3.

Critical nuance: Many dermal fillers contain lidocaine, a local anesthetic. In this case, the filler material provides the primary action (physical volume), while the lidocaine provides an ancillary action (pain relief). Under the medical device framework — consistent with EU MDR Article 1(8) and MDCG 2022-5 — this product remains a medical device with an ancillary medicinal substance, not a pharmaceutical product.

Step 3: Is the Product Listed in GN-00 Appendix 1?

If the product is an injectable dermal filler or mucous membrane filler, it is listed in GN-00 Appendix 1 and qualifies for MDACS listing as a medical device.

If the product is a different type of injectable (e.g., an injectable drug, biologic, or product not covered by Appendix 1), it remains a pharmaceutical product under Cap. 138.

Step 4: Confirm Classification With the MDD

Even after working through Steps 1–3, the MDD makes the final classification determination. For borderline products, it is advisable to seek pre-submission clarification from the MDD through your LRP.

Recommended Reading

Borderline Product Classification Across FDA, EU MDR, ANVISA, and COFEPRIS

Regulatory EU MDR / IVDR2026-04-10 · 25 min read

Comparative Analysis: How Other Jurisdictions Handle the Same Borderline

European Union

The EU provides the most developed framework for borderline classification of dermal fillers:

Dimension	EU MDR Approach
Medical device scope	Dermal fillers are medical devices under MDR, classified under Annex VIII Rules 7 and 8
Non-medical purpose	Dermal fillers without a medical purpose are covered under Annex XVI, Group 3 (products for facial or other dermal/mucous membrane filling by injection)
Classification	Class IIb (resorbable, long-term) or Class III (non-resorbable, or with ancillary medicinal substance like lidocaine)
Combination products	Fillers containing lidocaine are Class III combination products under Article 1(8); the medicinal substance must have ancillary action
Common Specifications	Commission Implementing Regulation (EU) 2022/2346 applies specific safety requirements for Annex XVI Group 3 products
Borderline manual	MDCG Borderline and Classification Manual (Version 5, April 2026) confirms dermal fillers as implantable devices

Key EU insight: The EU explicitly regulates dermal fillers regardless of whether they have a medical purpose. A wrinkle filler used purely for aesthetic enhancement is regulated identically to a filler used for HIV-related facial lipoatrophy. Hong Kong's GN-00 update adopts a similar principle.

United States

The FDA regulates dermal fillers as prescription medical devices:

Dimension	FDA Approach
Product codes	LMH (implant, dermal, for aesthetic use) and PKY (implant, dermal, for aesthetic use in the hands)
Classification	Class II (via 510(k) with special controls) or Class III (via PMA for newer materials)
Combination products	Fillers with lidocaine are regulated as combination products under the FDA's Office of Combination Products
Post-market	Medical Device Reporting (MDR) requirements apply; adverse events reported through MAUDE database
General wellness exclusion	FDA's 2026 General Wellness Guidance does not apply to injectable dermal fillers — they are prescription devices regardless of cosmetic intent

Key US insight: The FDA does not distinguish between medical and cosmetic purposes for dermal fillers. All injectable soft tissue fillers are regulated as medical devices. Hong Kong's approach is consistent with this position.

United Kingdom

The UK MHRA is moving toward stricter dermal filler regulation:

• In a 2022 consultation, 88% of respondents supported regulating dermal fillers under UK medical device regulations
• The MHRA confirmed it cannot regulate dermal fillers as prescription-only medicines because not all dermal fillers contain a medicinal substance
• The government proposed more stringent regulation under medical device rules, including restricting administration to healthcare professionals
• MHRA is preparing regulations to reclassify certain implantable devices and extend scope to capture non-medical products with similar risk profiles (e.g., dermal fillers, coloured contact lenses)

Mainland China

China's NMPA classifies injectable aesthetic fillers as Class III medical devices — the highest risk class — requiring clinical trials and rigorous pre-market review. Products approved as medical devices in China do not automatically receive the same classification in Hong Kong, as the two jurisdictions operate separate regulatory systems.

The Hong Kong Borderline in Practice: Product Scenarios

Scenario A: Hyaluronic Acid Dermal Filler (No Lidocaine)

• Composition: Cross-linked hyaluronic acid, prefilled syringe with needle
• Intended use: Correction of moderate to severe facial wrinkles and folds (nasolabial folds)
• Mode of action: Physical volume replacement
• Overseas approval: CE marked under EU MDR as Class IIb medical device
• Hong Kong classification: Medical device under GN-00 Appendix 1. Can be listed under MDACS via the reference country pathway using the EU CE certificate.
• Risk class: Likely Class II or Class III under TR-003

Scenario B: Hyaluronic Acid Filler With Lidocaine

• Composition: Cross-linked hyaluronic acid + 0.3% lidocaine HCl, prefilled syringe
• Intended use: Lip augmentation and facial contouring
• Mode of action: Physical volume replacement (primary) + local anesthesia (ancillary)
• Overseas approval: FDA 510(k) cleared as combination product
• Hong Kong classification: Medical device under GN-00 Appendix 1. The lidocaine provides ancillary action; the primary mode is physical. Consistent with EU MDR Article 1(8) treatment of combination products. Can be listed under MDACS.
• Risk class: Likely Class III under TR-003 (combination product with medicinal substance)

Scenario C: Botulinum Toxin (Botox-Type Product)

• Composition: Botulinum toxin type A, lyophilized powder for reconstitution
• Intended use: Temporary improvement in the appearance of moderate to severe glabellar lines
• Mode of action: Pharmacological — blocks neuromuscular transmission by inhibiting acetylcholine release
• Hong Kong classification: Pharmaceutical product under Cap. 138. The primary mode of action is pharmacological. This product is not covered by GN-00 Appendix 1 and cannot be listed as a medical device under MDACS. It must be registered as a pharmaceutical product with the Pharmacy and Poisons Board.

Scenario D: Topical Hyaluronic Acid Serum

• Composition: Non-cross-linked hyaluronic acid in aqueous solution, topical application
• Intended use: Skin hydration and temporary improvement in skin texture
• Mode of action: Physical (moisturizing film on skin surface)
• Hong Kong classification: Consumer product under Cap. 456. The product is not injectable and does not make medical claims. It is regulated as a cosmetic/consumer product.
• MDACS listing: Not applicable — the product is outside the scope of medical device regulation.

Scenario E: Injectable Poly-L-Lactic Acid (PLLA) Collagen Stimulator

• Composition: Poly-L-lactic acid microparticles suspended in aqueous carrier, reconstituted before injection
• Intended use: Restoration of facial volume through neocollagenesis
• Mode of action: Physical (particle scaffold) + biological (stimulates local collagen production)
• Hong Kong classification: Likely medical device under GN-00 Appendix 1, though the biological component requires careful analysis. If the primary intended action is considered physical (the PLLA particles provide structural volume), the product qualifies as a medical device. If the primary action is considered biological (collagen stimulation), the MDD may refer the product to the pharmaceutical framework. Pre-submission clarification with the MDD is strongly recommended.

Why This Borderline Analysis Matters in 2026

Three Concurrent Regulatory Developments

1. April 2026: Pharmacy and Poisons Board clarifies that injectable products are presumed pharmaceutical products — raising the regulatory bar for all injectable aesthetic products.
2. May 2026: GN-00 update carves out dermal fillers as medical devices — creating a listing pathway for products that would otherwise be stuck in a regulatory gap.
3. Ongoing: Hong Kong's planned transition to mandatory statutory regulation under the CMPR — expected 2026–2028 — will formalize these classifications and introduce registration fees.

Manufacturers who establish their classification position now — and secure MDACS listing where appropriate — will have a significant advantage during the statutory transition.

The Risk of Misclassification

Getting this wrong carries real consequences:

• Customs detention: Borderline products without clear classification face heightened risk of import delays or non-clearance following the April 2026 clarification.
• Enforcement action: Products marketed without proper registration or listing may face enforcement by the Department of Health.
• Market exclusion: Products that cannot be classified as either medical devices or pharmaceuticals may have no viable pathway to the Hong Kong market.
• Commercial liability: Distributors and clinics handling unregistered or misclassified products face their own regulatory exposure.

Recommended Reading

EU Digital Product Passport for Medical Devices: ESPR, Batteries, and UDI

Regulatory EU MDR / IVDR2026-06-01 · 14 min read

Practical Recommendations

Your Product	Recommended Action
Injectable HA filler, CE marked or FDA cleared	Pursue MDACS listing under GN-00 Appendix 1. Use reference country pathway. Budget US$6,000–17,000 over 3 years including LRP fees.
Injectable HA filler with lidocaine	Same as above. Ensure your technical documentation addresses the combination product aspect. Class III likely.
Injectable product with pharmacological mode of action (e.g., botulinum toxin, PRP)	Register as a pharmaceutical product under Cap. 138. MDACS listing is not available.
Injectable product with uncertain mode of action (e.g., PLLA, CaHA)	Seek pre-submission clarification from the MDD. Prepare documentation supporting medical device classification.
Topical cosmetic product	Regulated under Cap. 456. No MDACS listing required or available.
Injectable product currently on market without listing	Conduct urgent classification review. Pursue MDACS listing if eligible to regularize your market position.

Cost Comparison Across Pathways

Pathway	Typical Cost (3-Year Total, 1 Product)	Timeline
MDACS listing (medical device)	US$6,000–$17,000	12–18 months
Pharmaceutical registration under Cap. 138	Significantly higher; requires CPP, pharmaceutical quality dossier, clinical data	18–36+ months
No registration (informal market access)	$0 — but carries customs, enforcement, and liability risk	N/A

Pure Global's published Hong Kong pricing provides a transparent benchmark for the MDACS pathway: LRP services start at US$2,000/year for Class I/II listings and US$3,000/year for Class III/IV listings, excluding government fees (currently zero) and third-party fees. Source: Pure Global Pricing.

Related Resources

• Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices
• Hong Kong Dermal Filler MDACS Listing Strategy: LRP, Documentation, Importer Controls, and Procurement
• Borderline Product Classification Across FDA, EU MDR, ANVISA, and COFEPRIS
• MDCG 2026 Updates: Classification, EMDN Codes, and Borderline Guidance